Polaris Capital Management LLC Acquires 4,500 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Polaris Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,500 shares during the period. Polaris Capital Management LLC owned approximately 0.09% of Supernus Pharmaceuticals worth $1,700,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. GAMMA Investing LLC raised its position in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 398 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at $72,000. KBC Group NV raised its stake in Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 929 shares during the period. Finally, Kennebec Savings Bank acquired a new position in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $103,000.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $37.93 on Tuesday. The firm has a 50 day simple moving average of $37.38 and a two-hundred day simple moving average of $34.90. The company has a market cap of $2.09 billion, a P/E ratio of 35.45 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 9.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an “overweight” rating and a $57.00 price objective for the company. Finally, Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.